Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus

Katsuya Suzuki, Hideto Kameda, Koichi Amano, Hayato Nagasawa, Hirofumi Takei, Eiko Nishi, Ayumi Okuyama, Kensei Tsuzaka, Tsutomu Takeuchi

研究成果: Article査読

24 被引用数 (Scopus)

抄録

The aim of this study was to prospectively evaluate the efficacy and safety of tacrolimus (TAC) in various manifestations of systemic lupus erythematosus (SLE) patients in daily clinical practice. Each of the 21 TAC-treated patients with SLE in our care over 2 years was enrolled in this open-label trial. Patients were administered TAC at a dosage of 1-6 mg once daily, followed up for 24 weeks. Efficacy and safety were evaluated utilizing clinical and laboratory findings. As treatment targets, TAC was preferentially used with oral corticosteroid administration for mild active manifestations such as arthritis, skin eruptions, or asymptomatic nephritis. In efficacy, the mean value of the SLE disease activity index was significantly reduced to 4.1, 2.7, 1.8, and 1.2 (N = 21, 20, 16 and 13) at 0, 4, 12, and 24 weeks, respectively. In eight cases, treatment was discontinued within 24 weeks due to insufficient effects (6 cases) and side effects (2 cases). Non-serious side effects were observed in only five cases (23.8%) over 24 weeks. TAC can be considered both effective and safe for the treatment of various manifestations of SLE.

本文言語English
ページ(範囲)757-763
ページ数7
ジャーナルRheumatology International
31
6
DOI
出版ステータスPublished - 2011 6月

ASJC Scopus subject areas

  • リウマチ学
  • 免疫アレルギー学
  • 免疫学

フィンガープリント

「Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル